Metformin and Longevity in Women: A Potential Link to Exceptional Lifespans

Metformin, a widely prescribed medication for type 2 diabetes, may be associated with increased longevity in women, potentially extending life to age 90 or beyond, according to research published in 2025.

Metformin Shows Promise in Extending Exceptional Longevity

A study conducted by researchers in the US and Germany, published in the Journal of Gerontology: Medical Sciences, analyzed data from a long-term study of postmenopausal women. The research involved 438 participants, with half receiving metformin and the other half taking sulfonylurea, another common diabetes medication. Results indicated that women initiating metformin treatment had a 30% lower risk of death before the age of 90 compared to those treated with sulfonylurea [1].

How Metformin May Promote Longevity

Researchers suggest metformin’s potential benefits extend beyond diabetes management, attributing its effects to various anti-aging properties. “Metformin has been shown to target multiple pathways of aging and therefore has been postulated as a drug that may extend human longevity,” the study authors wrote [1]. Metformin is considered a gerotherapeutic – a drug capable of slowing down biological aging processes [2]. Previous studies have indicated it can reduce DNA damage and positively influence gene activity associated with longer lifespans [4].

Study Limitations and Future Research

The researchers acknowledge that the study cannot definitively prove a cause-and-effect relationship. The study design was not a randomized controlled trial (RCT), meaning participants were not randomly assigned to metformin or sulfonylurea; instead, they received treatment as recommended by their physicians. The study lacked a placebo group. However, the long follow-up period – averaging 14 to 15 years – is a significant strength, exceeding the duration of typical clinical trials [4].

The authors propose that future controlled clinical trials are needed to confirm whether metformin directly impacts longevity. Interest in drugs that can slow biological aging is growing, particularly in the context of an aging global population. The geroscience hypothesis suggests that slowing biological aging can delay or prevent age-related diseases [4].

Key Takeaways

• Metformin initiation was associated with a 30% lower risk of death before age 90 in women with type 2 diabetes compared to sulfonylurea initiation.
• Metformin is considered a gerotherapeutic, potentially slowing down biological aging processes.
• Further research, including randomized controlled trials, is needed to confirm metformin’s direct effects on longevity.